PAOLA-1 Final OS - Slideset Download - ESMO Congress Paris | CCO
Progression-free survival (PFS) and overall survival (OS) following... | Download Scientific Diagram
Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study | SpringerLink
Merck & Co., Inc. - SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Frontiers | Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
SOLO-1: Seven-Year Follow-up Data Confirm Maintenance Olaparib Benefit in Ovarian Cancer
ASCO: Final Overall Survival Results for Olaparib Maintenance in BRCA-Mutated Ovarian Cancer | PracticeUpdate
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
![PDF] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9314dd1346d2cc24326eae7876a44b50ea602b22/4-Figure1-1.png "PDF] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | Semantic Scholar")
PDF] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | Semantic Scholar
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer - Annals of Oncology
SGO on Twitter: "Improved overall survival with olaparib maintenance was clear - even when pts in the placebo group were treated with #PARPi in a later line - important information for sequencing
Efficacy of LYNPARZA® (olaparib) from Study 19
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM Evidence
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Cancer Research Highlight: PARP Inhibition Sets A New Benchmark For Ovarian Cancer (NASDAQ:AZN) | Seeking Alpha
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer - The ASCO Post
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - ScienceDirect
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
New applications of PARP inhibitors - memoinOncology
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
